The Approval Process in Action

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.

Miner Finds Promising Copper Breakthrough at Nevada Site
Source: Streetwise Reports (06/09/2025)

Giant Mining Corp.'s (CSE: BFG; OTC:BFGFF; FWB:YW5 AI-guided drilling at its Nevada copper project intersected high-grade zones, supporting a major update to its geological model. Read more about the potential resource expansion at Majuba Hill.

Explorer Uncovers Premium Gold-Silver Resource in South America
Source: Streetwise Reports (06/09/2025)

Canadian mineral exploration company Magma Silver Corp. (MGMA:TSX; FSE:BC21; WKN:A411DV) says it is picking up where majors like Newmont, Anglo Gold, and Bear Creek left off in Peru.

Precious Metals Miner Extends First Majestic Loan
Source: Streetwise Reports (06/06/2025)

Sierra Madre Gold and Silver Ltd. (SM:TSX.V; SMDRF:OTCQX) extended a US$5M loan, enabling expansion at its silver-gold Guitarra mine in Mexico amid strong sector momentum. Read more to see how silvers supply crunch and new production gains could boost long-term value.

US Supplier Secures Lease on Drone Motor Production Plant
Source: Streetwise Reports (06/06/2025)

Unusual Machines Inc. (UMAC:NYSE.American) will be able to build at scale and produce smaller customized batches at this 17,000-square-foot manufacturing facility in Florida. Find out why two analysts rate this company Buy.

Biotech Company Unlocks Gene Therapy Breakthrough in Canada
Source: Streetwise Reports (06/06/2025)

PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.